LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC) Life Science
First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT) Life Science